Antiviral Therapeutics Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI4608
Antiviral Therapeutics Market size is projected to witness significant growth from 2020 to 2026. Antiviral Therapeutics or antiviral drugs are prescription medicines that are available in the form of pills, intravenous solution & liquids and in inhaled powder form. These drugs are used for the treatment of viral infection. Antiviral drugs assist in reducing the risk of problems such as respiratory complications, ear infections in children and hospitalization of adults. These drugs work best after the onset of flu. Depending on the drug prescribed, duration of treatment differs from patient to patient.
Get more details on this report - Request Free Sample PDF
Rising number of patients suffering from viral infections and increasing prevalence of HIV infections has triggered the adoption of antiviral therapeutics across the globe. According to the recent data by Centers for Disease Control and Prevention (CDC), in 2016, more than 38,700 new HIV infections were found in the U.S. Majority of these HIV infected patients were between the age group of 25-34. Hence, owing to this the growing usage of antiviral drugs will help in enhancing the market growth in the near future.
Growing number of products in the pipeline for treatment of viral infections will positively contribute to the market growth. For instance, as per the recent data by the government of U.S., more than 5,000 drugs for the treatment of viral infections are in the pipeline. Moreover, several market players are focusing on manufacturing of drugs. However, increasing awareness of preventive procedures for viral infections will be one of the major factors restraining the market growth across the globe.
Based on drug class, the antiviral therapeutics market is categorized into neuraminidase inhibitor, DNA polymerase inhibitor, reverse transcriptase inhibitor and protease inhibitor. The reverse transcriptase inhibitor segment is expected to show lucrative growth over the forecast years owing to its effectivity in reducing viral infections. Therefore, the demand and use of reverse transcriptase inhibitor is projected to be high thereby, augmenting the market growth across the globe.
On the basis of application, the market is segmented as influenza, hepatitis, sexually transmitted diseases (STDs), respiratory tract infections and other applications. The hepatitis segment is expected to witness substantial growth over the forecast years. The rapid growth of this segment is owing to the factors such as increasing prevalence of hepatitis C in the U.S. and increasing focus on second generation direct acting antiviral agents. The sexually transmitted diseases segment is also one of the profitable segments as there is an increase in the prevalence of both Herpes Simplex Virus 1 (HSV-1) and Herpes Simplex Virus 2 (HSV-2) in the U.S.
Based on distribution channel, the antiviral therapeutics market is bifurcated into brick and mortar, hospital pharmacy and e-pharmacy. The e-pharmacy segment is anticipated to witness the highest growth in the projected years owing to the rapid growth in the number of internet users and increased access to online services across the globe. Hence, aforementioned factors will play vital role in boosting the market growth.
Asia Pacific antiviral therapeutics market is estimated to hold majority market share in the forecast timeframe owing to the factors such as rapid internet penetration and increasing spending on medicines. Moreover, increase in the number of non-communicable diseases and emerging viral infections will further fuel the market demand.
Some of the major market players involved in the global antiviral therapeutics market share are GlaxoSmithKline plc., Cipla, Gilead Sciences F. Hoffmann-La Roche Ltd, Bristol Myers Squibb, Aurobindo Pharma, Merck & Co., Johnson & Johnson Services, AbbVie, Schering-Plough Corporation among others. These players are constantly focusing on major strategies such as new product approvals, geographic expansion, mergers and acquisitions in order to strengthen their market position. For instance, in October 2019, Roche received the Food and Drug Administration (FDA) approval for its new drug application XofluzaTM (baloxavir marboxil) that is used for the treatment of acute influenza.
Antiviral Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
- Neuraminidase inhibitors
- DNA polymerase inhibitors
- Purine Nucleoside Analogues
- Pyrimidine Nucleoside Analogues
- Reverse transcriptase inhibitors
- Nucleoside RTIs
- Nonnucleoside RTIs
- Nucleotide RTIs
- Protease inhibitors
By Application, 2015-2026 (USD Million)
- Hepatitis B
- Hepatitis C
- Sexually Transmitted Diseases (STDs)
- Respiratory tract infection
By Distribution Channel, 2015-2026 (USD Million)
- Brick and mortar
- Hospital pharmacy
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- South Korea
- New Zealand
- Sri Lanka
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
- Gilead Sciences
- F. Hoffmann-La Roche Ltd
- Bristol Myers Squibb
- GlaxoSmithKline plc.
- Aurobindo Pharma
- Merck & Co.
- Johnson & Johnson Services
- Schering-Plough Corporation
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Benefits of Association
Data Coverage & Quality
GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.
Client Trust & Security
GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.
Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.